Drug Profile
PF 06804103
Alternative Names: anti-HER2 ADC; Anti-HER2 antibody-drug conjugate - Pfizer; anti-HER2-vc0101; anti-HER2-vcAur0101 ADC; Anti-NG-HER2 ADC; anti-NG-Her2-vc0101 ADC; NG-HER2 ADC; PF-06804103Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Aug 2021 Pfizer completes Phase-I trials for Solid tumours (Monotherapy) and Solid tumours (Combination therapy) in USA, Spain, South Korea, Russia, Italy, Australia (unspecified route) (NCT03284723)
- 28 Jul 2021 Discontinued - Phase-I for Solid tumours (Monotherapy) and Solid tumours (Combination therapy) in USA, Russia, Australia, Italy, Spain, South Korea (unspecified route) (Pfizer pipeline, July 2021)
- 17 Feb 2021 Phase I development is ongoing for Solid tumours (Monotherapy) and Solid tumours (Combination therapy) in South Korea, Spain, Italy and USA (Pfizer pipeline, February 2021) (EudraCT2017-002538-22) (NCT03284723)